Table 1 (Continued)
Trial | HbA1C (%) | eGFR (ml/ min/1.73 m2) | Duration of diabetes (years) | Median follow year (years) | eGFR < 60 ml/min per 1.73 m2, n (%) | Proportion of patients with established atherosclerotic cardiovascular disease, n (%) | |||
|---|---|---|---|---|---|---|---|---|---|
I | C | I | C | I | C | ||||
Finerenone vs. placebo | |||||||||
FIDELIO-DKD | 7.7 ± 1.3 | 7.7 ± 1.4 | 44.4 ± 12.5 | 44.3 ± 12.6 | 16.6 ± 8.8 | 16.6 ± 8.8 | 2.6 | 5016 (88.4) | 2605 (45.9) |
FIGARO-DKD | 7.7 ± 1.4 | 7.7 ± 1.4 | 67.6 ± 21.7 | 68.0 ± 21.7 | 14.5 ± 8.6 | 14.4 ± 8.4 | 3.4 | 2812 (38.3) | 3330 (45.3) |
ARTS-DN | 7.6 ± 1.3 | 7.6 ± 1.3 | 66.9 ± 21.9 | 72.2 ± 20.4 | N/A |  | N/A | 328 (40.0) | N/A |
GLP-1RA vs. placebo | |||||||||
ELIXA | 7.7 ± 1.3 | 7.6 ± 1.3 | 76.7 ± 21.3 | 75.2 ± 21.4 | 9.2 ± 8.2 | 9.4 ± 8.3 | 2.1 | 1407 (23.2) | 6068 (100.0) |
LEADER | 8.7 ± 1.6 | 8.7 ± 1.5 | 80.2 ± 27.2 | 80.5 ± 10.8 | 12.8 ± 8.0 | 12.9 ± 8.1 | 3.8 | 2158 (23.1) | 7598 (81.3) |
SUSTAIN-6 | 8.7 ± 1.5 | 8.7 ± 1.5 | 75.9 ± 25.9 | 76.4 ± 27.2 | 14.2 ± 8.2 | 13.6 ± 8.0 | 2.1 | 939 (28.5) | 2735 (83.0) |
EXSCEL | 8.1 ± 1.0 |  | 78.4 ± 24.1 |  | 13.1 ± 8.3 |  | 3.2 | 3191 (21.6) | 10,782 (73.1) |
HARMONY | 8.76 ± 1.5 | 8.72 ± 1.5 | 79.1 ± 25.6 | 78.9 ± 25.4 | 14.1 ± 8.6 | 14.2 ± 8.9 | 1.6 | N/A | 9463 (100.0) |
REWIND | 7.3 ± 1.1 | 7.4 ± 1.1 | 77.2 ± 22.7 | 76.6 ± 22.8 | 10.5 ± 7.3 | 10.6 ± 7.2 | 5.4 | 2199 (22.2) | 3114 (31.5) |
AMPLITUDE-O | 8.90 ± 1.46 | 8.94 ± 1.52 | 72.2 ± 21.9 | 72.9 ± 23.3 | 15.6 ± 8.8 | 15.1 ± 8.7 | 1.81 | N/A | 3650 (89.6) |
PIONEER 6 | 8.2 ± 1.6 | 8.2 ± 1.6 | 74 ± 21 | 74 ± 21 | 14.7 ± 8.5 | 15.1 ± 8.5 | N/A | 856 (26.9) | 2695 (84.7) |